143 related articles for article (PubMed ID: 12935804)
21. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
22. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
Caballero S; Nieto S; Gajardo R; Jorquera JI
Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
[TBL] [Abstract][Full Text] [Related]
23. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
24. Purification and large-scale preparation of antithrombin III.
Hoffman DL
Am J Med; 1989 Sep; 87(3B):23S-26S. PubMed ID: 2801726
[TBL] [Abstract][Full Text] [Related]
25. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
26. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
27. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
28. Manufacturing process for antithrombin III concentrate: viral validation studies and effects of column re-use on viral safety.
Falbo A
Dev Biol (Basel); 2003; 113():81-8. PubMed ID: 14620856
[No Abstract] [Full Text] [Related]
29. Avoiding viral contamination in biotechnological and pharmaceutical processes.
Henzler HJ; Kaiser K
Nat Biotechnol; 1998 Nov; 16(11):1077-9. PubMed ID: 9831040
[No Abstract] [Full Text] [Related]
30. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
Burnouf T; Terpstra F; Habib G; Seddik S
Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
[TBL] [Abstract][Full Text] [Related]
31. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
Ma J; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
[TBL] [Abstract][Full Text] [Related]
32. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
33. The Sterways process: a new approach to inactivating viruses using gamma radiation.
Reid BD
Biologicals; 1998 Jun; 26(2):125-9. PubMed ID: 9811518
[TBL] [Abstract][Full Text] [Related]
34. A pasteurized antithrombin III concentrate for clinical use.
Smith JK; Winkelman L; Evans DR; Haddon ME; Sims G
Vox Sang; 1985; 48(6):325-32. PubMed ID: 4013136
[TBL] [Abstract][Full Text] [Related]
35. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
36. Development of large scale fractionation methods. VII. Preparation of antithrombin III concentrate.
Wickerhauser M; Williams C; Mercer J
Vox Sang; 1979; 36(5):281-93. PubMed ID: 462917
[TBL] [Abstract][Full Text] [Related]
37. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
38. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses.
Valdés R; Ibarra N; Ruibal I; Beldarraín A; Noa E; Herrera N; Alemán R; Padilla S; Garcia J; Pérez M; Morales R; Chong E; Reyes B; Quiñones Y; Agraz A; Herrera L
J Biotechnol; 2002 Jul; 96(3):251-8. PubMed ID: 12044553
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
40. Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb) for viral inactivation--effect of crosslinking.
Azari M; Catarello J; Burhop K; Camacho T; Ebeling A; Estep T; Guzder S; Krause K; Marshall T; Rohn K; Sarajari R; Boose JA; Gauvin G; Horner R; Lu B; Pearson L; Vacante D
Artif Cells Blood Substit Immobil Biotechnol; 1997 Nov; 25(6):521-6. PubMed ID: 9352057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
